Skip to content

About
Our Science
Research and Development
News
Careers and Culture

Menu

About
Our Science
Research and Development
News
Careers and Culture

News and Events

February 17, 2022

Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer

October 27, 2021

Cardurion Pharmaceuticals Announces Investment of up to $300 Million from Bain Capital

January 19, 2021

Cardurion Pharmaceuticals Announces Appointment of Howard K. Surks, M.D., as Chief Scientific Officer and Head, Translational Medicine

July 9, 2020

Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer

April 22, 2020

Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer

November 20, 2019

Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors

November 12, 2018

Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models

October 2, 2018

Silvia Priori, M.D., Ph.D. Delivers the William Harvey Lecture on Basic Science

September 20, 2018

Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure

Media and Investor Contact Information

To request additional information or contact us, please email: info@cardurion.com.

Contact Us
Privacy Policy
Terms of Use

Contact Us
Privacy Policy
Terms of Use

©2024 Cardurion Pharmaceuticals. All rights reserved.

This site uses cookies and third-party scripts to provide certain services. View Privacy Policy

Skip to content